Register to Join 600+ Pharma and Biotech Leaders, Venture Capitalists, Media and Policymakers in New York City, October 13-15, 2025

Demy-Colton today unveiled a dynamic agenda for its BioFuture™ 2025 conference, returning to Cure, New York City’s leading health innovation hub, October 13–15, 2025. A virtual partnering component will follow October 21–23, offering global participants access to recorded sessions and one-on-one virtual meetings.

This year’s program will gather biotech, pharma, digital medicine, TechBio, healthcare delivery, policy and investment leaders to discuss how new innovation, policy, technology, and capital markets are reshaping the healthcare ecosystem. The lineup includes influential speakers from Deerfield, Scientific American, Acadia Pharmaceuticals, Endpoints News, Jefferies, Northwell Health, Stifel, Regeneron, Ernst & Young, Amazon, and Business Insider among many others.

Session highlights include:

• The Great Biopharma Reset: Will Today’s Challenging Environment Result in a More Resilient Sector? featuring Dennis Purcell, Founder & Senior Advisor, Aisling Capital; Jo Natauri, Founder & Managing Partner, Invidia Capital Management; Umer Raffat, Equity Research, Evercore ISI; Philip Ross, Vice Chairman, Global Healthcare Investment Banking, Jefferies LLC; and Eric Schmidt, Biotechnology Analyst, Cantor Fitzgerald.

• Rewiring Minds: Breakthroughs in Brain & CNS Health featuring Walter Greenleaf, Stanford University; Connor Glass, CEO & Founder, Phantom Neuro; Beth Hoffman, CEO, Origami Therapeutics; Adam Rogers, CEO, NervGen Pharma; Arun Swaminathan, CEO, Coya Therapeutics; Brent Vaughan, CEO & Founder, Eratos Therapeutics.

• Global Strategy in Transition: Opportunities and Risks in China featuring Mike Patten, Chief Strategy Officer, Harbour BioMed; Raven Lin, CEO & Director, Pilatus Biosciences; Tim Opler, Managing Director, Global Healthcare Group, Stifel; Echo Hindle-Yang, Founder & CEO, MSQ Ventures; Lihua Zheng, Co-Founder & CEO, Z-Star Therapeutics Inc.

“BioFuture has become a must-attend event that provides leading investors, innovators, industry media, regulators, policymakers, and biopharmaceutical executives with the strategic insights and powerful relationships needed to succeed in today’s rapidly evolving healthcare ecosystem,” said Sara Demy, Founder & CEO of Demy-Colton. “The conference has earned a reputation for unmatched networking opportunities and for leaning into the tough discussions that matter most. We’ve carefully curated this year’s agenda to reflect the challenges and opportunities ahead, and we are excited to bring together the people who are shaping the future of the biopharma industry.”

Demy-Colton encourages innovative public and private biotech, techbio, digital medicine and AI/ML companies to register to attend or apply to present. Qualified investors and media are encouraged to apply for complimentary registration. For more information about registering for the event, presenting opportunities, or sponsorships, visit www.biofuture.com and follow #BioFuture2025 on X.

About Demy-Colton

Demy-Colton is a leading life sciences and digital health events organization at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Global Biotech CEO Summit™, Executive Clinics™, and Demy-Colton Virtual Salons™. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders. For more information, visit www.demy-colton.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250923415173/en/

BioFuture™ has earned a reputation for unmatched networking opportunities and for leaning into the tough discussions that matter most.